期刊文献+

十肽表位HPV-16E7_(11-20)氨基酸置换修饰的研究 被引量:6

Modification of amino acid substitution of the epitope HPV-16ET7_(11-20)
原文传递
导出
摘要 目的采用氨基酸置换对人乳头状瘤病毒16型E7抗原的人白细胞抗原A2分子限制性细胞毒性T细胞表位HPV-16E7_(11-20)进行修饰和鉴定。方法运用量化模体方案对置换后的多肽与人白细胞抗原A2分子的结合系数进行比较,以分子模拟方法确定合成序列,采用标准Fmoc方案进行合成与纯化多肽以及标准^(51)Cr释放试验检测特异性细胞毒性T细胞诱导活性。结果修饰多肽符合人白细胞抗原A2分子限制性细胞毒性T细胞的表位要求,十肽YLLDLQPEVT具有特异性细胞毒性T细胞诱导活性。结论修饰表位YLLDLQPEVT具有更好的结合力和较强的抗原性,可以代替原有序列E7_(11-20)(YMLDLQPETT)作为人乳头状瘤病毒感染治疗性肽疫苗分子设计的新表位。 Objective To identify novel epitopes by modification of amino acid substitution of HLA-A2- restricted CTL epitope HPV-16E7 11-20. Methods Quantitative method was used to evaluate the affinity of substitated peptides. To determine the peptide candidates to be synthesized and identified, the molecular models of CTL epitope candidates bound to the HLA-A2 molecule and of the HLA-A2-peptide complex were established by computer molecular modeling. Pepfides were synthesized and purified with standard Fmoc assay. The standard ^51Cr release assay was used to demonstrate their capability of inducing the generation of specific CTL. Results Pepfides modified met the condition of HLA-A2-restricted CTL epitopes. Peptide YLLDLQPEVT had the capability of indueing the generation of specific CTL. Conclusion The modified peptide YLLDLQPEVT had the higher affinity HLA- A2 and antigenicity compared with HPV-16E7 11-20 - So peptide YLLDLQPEVT could be one of the novel HLA-A2- restricted epitopes, as an alternative of HPV-16E7 11-20, for peptide vaccine in HPV infection treatment.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2006年第11期990-993,共4页 Chinese Journal of Microbiology and Immunology
基金 国家自然科学基金(30500537 30070698)
关键词 人乳头状瘤病毒 E7抗原 T淋巴细胞表位 分子修饰 Human papillomavims E7 antigen Epitopes, T-lymphocyte Molecular modification
  • 引文网络
  • 相关文献

参考文献12

  • 1Nilges K,Hohn H,Pilch H,et al.Human papillomavirus type 16E7peptide-directed CD8^+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.J Virol,2003,77(9):5464-5474. 被引量:1
  • 2李艳佳,齐凤英,左连富,郭建文,张俊峰,宣晓梅,陈兴宽.人乳头瘤病毒16型E7基因修饰小鼠骨髓树突状细胞诱导的细胞免疫应答[J].中华微生物学和免疫学杂志,2005,25(2):136-136. 被引量:2
  • 3Okubo M,Saito M,Inoku H,et al.Analysis of HLA-DRB1 * 0901-binding HPV-16 E7 helper T cell epitope.J Obstet Gynaecol Res,2004,30(2):120-129. 被引量:1
  • 4Kotecha MT,Afghan RK,Vasilikopoulou E,et al.Enhanced tumour growth after DNA vaccination against human papillomavirus E7 oncoprotein:evidence for tumour-induced immune deviation.Vaccine,2003,21(19-20):2506-2515. 被引量:1
  • 5Herd KA,Harvey T,Khromykh AA,et al.Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.Virology.2004,319(2):237-248. 被引量:1
  • 6魏兰兰,谷鸿喜,初明,王燕,庄敏,商庆龙,凌虹,张凤民.人乳头瘤病毒16型晚期蛋白L1的表达及病毒样颗粒的装配[J].中华微生物学和免疫学杂志,2004,24(5):383-387. 被引量:4
  • 7Liu XS,Xu Y,Hardy L,et al.IL-10 mediates suppression of the CD8 Tcell IFN-gamma response to a novel viral epitope in a primed host.J Immunol,2003,171(9):4765-4772. 被引量:1
  • 8Hoffmann TK,Donnenberg AD,Finkelstein SD,et al.Frequencies of tetramer^+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.Cancer Res,2002,62(12):3521-3529. 被引量:1
  • 9Wiethe C,Dittmar K,Doan T,etal.Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.J Immunol,2003,170(6):2912-2922. 被引量:1
  • 10徐云升,郝飞,宋志强,钟白玉,郝进,叶庆佾.HPV16E7抗原的HLA-A2限制性细胞毒性T淋巴细胞表位的筛选与鉴定[J].中华皮肤科杂志,2004,37(5):283-284. 被引量:6

二级参考文献20

  • 1Stanley MA.Progress in prophylactic and therapeutic vaccines for human papillomavirus infection.Expert Rev Vaccines,2003,2(3):381-389. 被引量:1
  • 2Sasagawa T,Pushko P,Steers G,et al.Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe.Virology,1995,206(1):126-135. 被引量:1
  • 3Warzecha H,Mason HS,Lane C,et al.Oral immunogenicity of human papillomavirus-like particles expressed in potato.J Virol,2003,77(16):8702-8711. 被引量:1
  • 4Bernard HU,Chan SY,Manos MM,et al.Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification,restriction fragment length polymorphisms,nucleotide sequence,and phylogenetic algorithms.J Infect Dis,199 被引量:1
  • 5Yamada T,Manos MM,Peto J,et al.Human papillomavirus type 16 sequence variation in cervical cancers:a worldwide perspective.J Virol,1997,71(3):2463-2472. 被引量:1
  • 6Sasagawa T,Pushko P,Steers G,et al.Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe.Virology,1995,206(1):126-135. 被引量:1
  • 7Kawana K,Kawana Y,Yoshikawa H,et al.Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.Vaccine,2001,19(11-12):1496-1502. 被引量:1
  • 8Schafer K,Muller M,Faath S,et al.Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles:induction of cytotoxic T cells and specific tumor protection.Int J Cancer,1999,81(6):881-888. 被引量:1
  • 9Nieland JD,Da Silva DM,Velders MP,et al.Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response.Cell Biochem,1999,73(2):145-152. 被引量:1
  • 10Chackerian B,Lowy DR,Schiller JT.Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.Proc Natl Acad Sci USA,1999,96(5):2373-2378. 被引量:1

共引文献9

同被引文献52

引证文献6

二级引证文献7

;
使用帮助 返回顶部